Printer Friendly

Research and Markets: Overview of the European Drug Discovery Market: Scope for New Drug Targets Discovery in the Drug Discovery Industry Ridden with Challenges.

DUBLIN -- Research and Markets ( has announced the addition of Frost & Sullivan's new report "Overview of the European Drug Discovery Market" to their offering.

This Frost & Sullivan research service titled Overview of the European Drug Discovery Market provides an overview of the drug discovery market together with the revenues generated in western Europe from 2007 to 2014. In addition, it provides a complete analysis of the key market drivers, industry challenges and market trends. Finally, it provides strategic solutions to vendors to gain advantage in this growing market. The research also examines opportunities in eastern Europe. In this research, Frost & Sullivan's expert analysts thoroughly examine the following areas: basic research, screening and process development.

Market Overview

Rising costs, a limited drug pipeline and the impeding loss of patent coverage for 'blockbuster' drugs are altering the landscape of pharmaceutical science. Factors such as the Human Genome Project, combinatorial chemistry, ongoing merger and acquisition (M&A) activity and partnerships between pharmaceutical and biotechnology companies further contribute to the scale and complexity associated with drug discovery. Astute business strategies are the need to overcome these challenges. Molecular biology has revolutionised the process of drug discovery. Today, the collaborative contribution of genomics, proteomics, combinatorial chemistry and bioinformatics allows for rapid and precise discovery of the respective genes and proteins. Additionally, using robotics, liquid handling devices, sensitive detectors, data processing and control software and high-throughput screening (HTS) allows researchers to conduct millions of biochemical, genetic or pharmacological tests. The trends in HTS have been toward testing compounds in cell-based and biochemical assays at increasing rates and in small volumes. The anticipated advantages are that more leads will be found in reduced time, with less reagent use, and larger libraries could be screened, thus increasing the information content of the screen and the odds of finding good leads.

Miniaturisation Technologies to Step up R&D Cycle and Reduce Costs

Miniaturisation technologies are integral to the rapidly growing laboratory instrumentation sector for applications in drug discovery, biotechnology, medical diagnostics and environmental studies. The miniaturisation process itself leads to a demand for new instruments and tools capable of handling micro litre quantities of biological fluids and expensive reagents, resulting in increased throughput, accuracy and efficiency with the simultaneous reduction of costs. The pharmaceutical industry has adopted assay miniaturisation in HTS to accelerate the R&D cycle and to minimise costs by reducing regent/consumable usage to a few micro litres. The numbers of new drugs that reach the market are dwindling each year and, in recent years, several drugs have been withdrawn from the market due to safety concerns. Since 1997, more than a dozen prescription drugs, including Pondimin, Redux, Seldane, Posicor, Duracht, Hismanal, Raxar, Rezulin, Propulsid, Lotronex, Raplon and Baycol, with serious side effects, have been taken off the shelves. It is estimated that 72 per cent of clinical candidates fail during the development stage with the estimated costs due to poor absorption, distribution, metabolism and excretion/toxicity (ADME/Tox) properties pegged at nearly $50 to $70 million. A major drawback to the current lead optimisation step is the time-consuming manner of understanding the ADME/Tox profiles of compounds.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sector in this research:

* Biotech


The following technologies are covered in this research:

* Contract research organisations (CROs)

* Biomarkers

* Fragment-based drug discovery

* Label-free technology

* High content screening (HCS)

* High-throughput screening (HTS)

* Predictive drug discovery (In silico)

Key Topics Covered:








For more information visit
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Industry overview
Date:May 13, 2009
Previous Article:COADE Releases CADWorx Design Create and CADWorx Design Viewer for Publishing and Viewing Date-Limited, Password Protected Review Models.
Next Article:Research and Markets: End Game: Europe's Energy Markets after the Third Package.

Related Articles
New drug discovery and development.
European Cell Based Assays Markets Face a Tough Challenge in Identifying Novel Drug Candidates in Drug Discovery.
Advances in Cell Based Assays Offer Promise for the Discovery of New Drug Candidates.
Research and Markets: Cell-Based Assays for Drug Discovery.
Research and Markets: Chinese Markets for Lymphoma Treatment Drugs.
Label-free screening of small molecular weight drugs: bringing new drugs to market is an expensive and time-consuming process, and even with HTS...
Research and Markets: The Global Bioinformatics Market - A Comprehensive Report on Market Size, Forecasts and Company Profiles.
Research and Markets: European Biomarker Analysis Market - Biomarkers to Aid Reduction of Drug Development Time and Costs.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters